Latest News and Press Releases

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15%.

WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.

Arcutis today announced that management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10-13, 2024.

Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.

Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.

WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.